New drug duo targets Tough-to-Treat breast cancer
NCT ID NCT07193394
Summary
This study is testing whether a combination of two existing cancer drugs, tucatinib and trastuzumab, can help control advanced breast cancer that has a specific genetic change (an ERBB3/HER3 mutation) but is not the typical HER2-positive type. It is for people whose cancer has spread or cannot be removed by surgery and has continued to grow despite at least two prior rounds of chemotherapy. All participants will receive the two-drug combination in three-week cycles to see if it slows or shrinks their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER ( HER2 NEGATIVE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Nîmes
NOT_YET_RECRUITINGNîmes, 30 029, France
Contact
Contact
-
Centre Antoine Lacassagne
NOT_YET_RECRUITINGNice, 06 189, France
Contact
Contact
-
Centre Eugène Marquis
NOT_YET_RECRUITINGRennes, 35 042, France
Contact
Contact
-
Chu Dupuytren- Limoges
NOT_YET_RECRUITINGLimoges, 87 042, France
Contact
Contact
-
Institut Curie_ Site Saint-Cloud
RECRUITINGSaint-Cloud, 92 210, France
Contact
Contact
-
Institut Paoli-Calmettes
NOT_YET_RECRUITINGMarseille, 13009, France
Contact
Contact
-
Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole Claudius Regaud
NOT_YET_RECRUITINGToulouse, 31 059, France
Contact
Contact
-
Institut de Cancérologie de Lorraine
NOT_YET_RECRUITINGVandœuvre-lès-Nancy, 54 519, France
Contact
Contact
-
Polyclinique Bordeaux Nord Aquitaine
NOT_YET_RECRUITINGBordeaux, 33 300, France
Contact
Contact
Conditions
Explore the condition pages connected to this study.